Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions

被引：146
作者：
Delgado, Mario [1 ]
Ganea, Doina [2 ]
机构：
[1] IPBLN CSIC, Inst Parasitol & Biomed, Granada, Spain
[2] Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19122 USA
来源：
AMINO ACIDS | 2013年 / 45卷 / 01期
关键词：
Vasoactive intestinal peptide; Autoimmunity; Inflammation; Neuroinflammation; Neuropeptides/neurotransmitters; CYCLASE-ACTIVATING POLYPEPTIDE; REGULATORY DENDRITIC CELLS; MEKK1/MEK4/JNK SIGNALING PATHWAY; T-CELLS; CHEMOKINE PRODUCTION; INDUCED NEURODEGENERATION; EXPERIMENTAL ARTHRITIS; RHEUMATOID-ARTHRITIS; ALTERED EXPRESSION; CUTTING EDGE;
D O I：
10.1007/s00726-011-1184-8
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Vasoactive intestinal peptide (VIP), a 28-amino acid neuropeptide/neurotransmitter, is widely distributed in both the central and peripheral nervous system. VIP is released by both neurons and immune cells. Various cell types, including immune cells, express VIP receptors. VIP has pleiotropic effects as a neurotransmitter, immune regulator, vasodilator and secretagogue. This review is focused on VIP production and effects on immune cells, VIP receptor signaling as related to immune functions, and the involvement of VIP in inflammatory and autoimmune disorders. The review addresses present clinical use of VIP and future therapeutic directions.
引用
收藏
页码：25 / 39
页数：15
相关论文
共 124 条
[41]   The role of VIP/PACAP receptor subtypes in spinal somatosensory processing in rats with an experimental peripheral mononeuropathy [J].
Dickinson, T ;
Mitchell, R ;
Robberecht, P ;
Fleetwood-Walker, SM .
NEUROPHARMACOLOGY, 1999, 38 (01) :167-180
[42]   VPAC and PAC receptors: From ligands to function [J].
Dickson, Louise ;
Finlayson, Keith .
PHARMACOLOGY & THERAPEUTICS, 2009, 121 (03) :294-316
[43]  
Dinsmore WW, 1999, BJU INT, V83, P274
[44]   Antimicrobial activity of neuropeptides against a range of micro-organisms from skin, oral, respiratory and gastrointestinal tract sites [J].
El Karim, Ikhlas A. ;
Linden, Gerard J. ;
Orr, David F. ;
Lundy, Fionnuala T. .
JOURNAL OF NEUROIMMUNOLOGY, 2008, 200 (1-2) :11-16
[45]  
Fahrenkrug J, 2010, RESULTS PROBL CELL D, V50, P221, DOI 10.1007/400_2009_24
[46]   Involvement of VIP and PACAP in neonatal brain lesions generated by a combined excitotoxic/inflammatory challenge [J].
Favrais, Geraldine ;
Couvineau, Alain ;
Laburthe, Marc ;
Gressens, Pierre ;
Lelievre, Vincent .
PEPTIDES, 2007, 28 (09) :1727-1737
[47]   VIP prevents experimental multiple sclerosis by downregulating both inflammatory and autoimmune components of the disease [J].
Fernandez-Martin, Amelia ;
Gonzalez-Rey, Elena ;
Chorny, Alejo ;
Martin, Javier ;
Pozo, David ;
Ganea, Doina ;
Delgado, Mario .
VIP, PACAP, AND RELATED PEPTIDES: FROM GENE TO THERAPY, 2006, 1070 :276-+
[48]  
Ferraccioli G, 2011, DISCOV MED, V11, P413
[49]   Pivotal Advance: Vasoactive intestinal peptide inhibits up-regulation of human monocyte TLR2 and TLR4 by LPS and differentiation of monocytes to macrophages [J].
Foster, N. ;
Lea, S. R. ;
Preshaw, P. M. ;
Taylor, J. J. .
JOURNAL OF LEUKOCYTE BIOLOGY, 2007, 81 (04) :893-903
[50]   VIP modulates the pro-inflammatory maternal response, inducing tolerance to trophoblast cells [J].
Fraccaroli, Laura ;
Alfieri, Julio ;
Larocca, Luciana ;
Calafat, Mario ;
Roca, Valeria ;
Lombardi, Eduardo ;
Ramhorst, Rosanna ;
Perez Leiros, Claudia .
BRITISH JOURNAL OF PHARMACOLOGY, 2009, 156 (01) :116-126
12345678910